Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain McGregor

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nursing Older People|October 8, 2016
Ensuring access to specialist care is fairIain McGregor
Nursing Older People|October 13, 2016
Forum focusIain McGregor
The Lancet. Public Health|October 14, 2018
Cannabis use and non-cancer chronic painIain McGregor
Heart (British Cardiac Society)|July 13, 2019
Renal denervation therapy for hypertension: still on trialIain McGregor MacIntyre, David John Webb
British Journal of Pharmacology|March 28, 2022
Inhibition of human recombinant T-type calcium channels by phytocannabinoids in vitroSomayeh Mirlohi, Chris Bladen, Marina J Santiago, et al.
Substance Abuse Treatment, Prevention, and Policy|October 8, 2022
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorderLlewellyn Mills, Adrian Dunlop, Mark Montebello, et al.
Microcirculation (New York, N.Y. : 1994)|March 17, 2007
Inflammation and breakdown of the blood-retinal barrier during "physiological aging" in the rat retina: a model for CNS agingTailoi Chan-Ling, Suzanne Hughes, Louise Baxter, et al.
Drug and Alcohol Dependence|March 22, 2022
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trialMark Montebello, Meryem Jefferies, Llewellyn Mills, et al.
Drug and Alcohol Dependence|August 10, 2020
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trialNicholas Lintzeris, Llewellyn Mills, Adrian Dunlop, et al.
BMJ Open|August 23, 2023
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trialIsobel Lavender, Danielle McCartney, Nathaniel Marshall, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nursing Older People|October 8, 2016
Ensuring access to specialist care is fairIain McGregor
Nursing Older People|October 13, 2016
Forum focusIain McGregor
The Lancet. Public Health|October 14, 2018
Cannabis use and non-cancer chronic painIain McGregor
Heart (British Cardiac Society)|July 13, 2019
Renal denervation therapy for hypertension: still on trialIain McGregor MacIntyre, David John Webb
British Journal of Pharmacology|March 28, 2022
Inhibition of human recombinant T-type calcium channels by phytocannabinoids in vitroSomayeh Mirlohi, Chris Bladen, Marina J Santiago, et al.
Substance Abuse Treatment, Prevention, and Policy|October 8, 2022
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorderLlewellyn Mills, Adrian Dunlop, Mark Montebello, et al.
Microcirculation (New York, N.Y. : 1994)|March 17, 2007
Inflammation and breakdown of the blood-retinal barrier during "physiological aging" in the rat retina: a model for CNS agingTailoi Chan-Ling, Suzanne Hughes, Louise Baxter, et al.
Drug and Alcohol Dependence|March 22, 2022
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trialMark Montebello, Meryem Jefferies, Llewellyn Mills, et al.
Drug and Alcohol Dependence|August 10, 2020
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trialNicholas Lintzeris, Llewellyn Mills, Adrian Dunlop, et al.
BMJ Open|August 23, 2023
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trialIsobel Lavender, Danielle McCartney, Nathaniel Marshall, et al.
Pageof 2